Literature DB >> 27496312

Hodgkin lymphoma in the elderly, pregnant, and HIV-infected.

Veronika Bachanova1, Joseph M Connors2.   

Abstract

Hodgkin lymphoma (HL) presenting in patients with co-incidental advanced age, pregnancy, or human immunodeficiency virus (HIV) infection is uniquely challenging to manage. In this article we integrate recent evidence and clinical expertise to present recommendations for diagnosis and therapeutic management. Older patients with HL need to be carefully evaluated for comorbidies after which judicious choice of chemotherapy should minimize functional compromise. A pregnant patient with concurrent HL should be staged with minimal use of imaging requiring ionizing radiation and treated in an individualized manner optimally combining the strategies of treatment deferral when appropriate, use of single-agent vinblastine for symptomatic disease and reservation of multi-agent chemotherapy for the small minority of patients with aggressive clinical presentation. Treatment of HL coincident with HIV infection requires a combination of highly active anti-retroviral agents (HAART), standard multi-agent chemotherapy with meticulous attention to drug-drug interactions, and vigorous supportive care to ensure the best chance of cure.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elderly; HIV; Hodgkin lymphoma; Pregnancy; Treatment

Mesh:

Year:  2016        PMID: 27496312      PMCID: PMC5568247          DOI: 10.1053/j.seminhematol.2016.05.002

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  48 in total

1.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Authors:  Andres Forero-Torres; Beata Holkova; Jerome Goldschmidt; Robert Chen; Gregg Olsen; Ralph V Boccia; Rodolfo E Bordoni; Jonathan W Friedberg; Jeff P Sharman; Maria Corinna Palanca-Wessels; Yinghui Wang; Christopher A Yasenchak
Journal:  Blood       Date:  2015-09-16       Impact factor: 22.113

Review 2.  Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

Authors:  Martine Extermann; Matti Aapro; Roberto Bernabei; Harvey Jay Cohen; Jean-Pierre Droz; Stuart Lichtman; Vincent Mor; Silvio Monfardini; Lazzaro Repetto; Liv Sørbye; Eva Topinkova
Journal:  Crit Rev Oncol Hematol       Date:  2005-09       Impact factor: 6.312

3.  Pregnancy-associated lymphomas. A clinicopathologic study.

Authors:  A B Gelb; M van de Rijn; R A Warnke; O W Kamel
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

4.  Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).

Authors:  A M Levine; P Li; T Cheung; A Tulpule; J Von Roenn; B N Nathwani; L Ratner
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-15       Impact factor: 3.731

Review 5.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

6.  Hodgkin lymphoma among patients infected with HIV in post-HAART era.

Authors:  Paula Yurie Tanaka; Vicente Porfírio Pessoa; Luis Fernando Pracchia; Valeria Buccheri; Dalton Alencar Fisher Chamone; Edenilson Eduardo Calore
Journal:  Clin Lymphoma Myeloma       Date:  2007-03

7.  Management of coexisting Hodgkin's disease and pregnancy.

Authors:  L Z Nisce; M A Tome; S He; B J Lee; G J Kutcher
Journal:  Am J Clin Oncol       Date:  1986-04       Impact factor: 2.339

8.  Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Authors:  Boris Böll; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Felicitas Hitz; Andrea Kerkhoff; Richard Greil; Bastian von Tresckow; Dennis A Eichenauer; Carolin Bürkle; Sven Borchmann; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann
Journal:  Blood       Date:  2016-02-01       Impact factor: 22.113

9.  ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group.

Authors: 
Journal:  Ann Oncol       Date:  1995-02       Impact factor: 32.976

10.  Maternal and foetal outcome following Hodgkin's disease in pregnancy.

Authors:  M Lishner; D Zemlickis; P Degendorfer; T Panzarella; S B Sutcliffe; G Koren
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  4 in total

1.  Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.

Authors:  Melody Becnel; Christopher R Flowers; Loretta J Nastoupil
Journal:  Ann Lymphoma       Date:  2017-11-17

2.  Coconut Oil Extract Mitigates Testicular Injury Following Adjuvant Treatment with Antiretroviral Drugs.

Authors:  Oluwatosin O Ogedengbe; Ayoola I Jegede; Ismail O Onanuga; Ugochukwu Offor; Edwin Cs Naidu; Aniekan I Peter; Onyemaechi O Azu
Journal:  Toxicol Res       Date:  2016-10-30

3.  The clinical features and prognosis of 100 AIDS-related lymphoma cases.

Authors:  Dedong Wu; Chen Chen; Mingzhi Zhang; Zhaoming Li; Suqian Wang; Jijing Shi; Yu Zhang; Dingzhu Yao; Shuang Hu
Journal:  Sci Rep       Date:  2019-03-29       Impact factor: 4.379

4.  Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis.

Authors:  Raissa Bila Cabral Fagundes; Leno Goes Delgado de Mederios; Amaxsell Thiago Barros de Souza; Maria Isabel Oliveira da Silva; Matheus Jose Barbosa Moreira; Carolina Colaço Villarrim; Irami Araújo-Filho; Kleyton Santos Medeiros
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.